Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) unit Shandong Zibo Xincat Pharmaceutical recently obtained approval of azithromycin for suspension from China's National Medical Products Administration after it passed the regulator's quality and efficacy consistency evaluation, a Tuesday bourse filing said.
Azithromycin is a macrolide antibiotic suitable for the treatment of mild-to-moderate infections caused by certain designated microbial sensitive strains, according to the pharmaceuticals and chemical products company.